87 0

Full metadata record

DC FieldValueLanguage
dc.contributor.author이영열-
dc.date.accessioned2019-12-03T04:22:10Z-
dc.date.available2019-12-03T04:22:10Z-
dc.date.issued2017-12-
dc.identifier.citationINTERNATIONAL JOURNAL OF ONCOLOGY, v. 51, no. 6, page. 1739-1746en_US
dc.identifier.issn1019-6439-
dc.identifier.issn1791-2423-
dc.identifier.urihttps://www.spandidos-publications.com/10.3892/ijo.2017.4161-
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/116762-
dc.description.abstractKML001 (sodium metaarsenite; NaAs2O3) is known to have antitumor activity against a variety of cancers. In this study, we examined its effect on multiple myeloma (MM). KML001 reduced the growth of all MM cell lines examined with an IC50 of 5x10(-8) M. Exposure to KML001 (5x10(-8) M) decreased levels of cyclins A/B1/D1/E1, CDK2/4/6 in U266 cells and increased the p21 and p27 levels. Furthermore, p21 became bound to CDK2/4/6, resulting in a reduction of CDK2/4/6 kinase activity. The cleaved forms of Bcl-2, and caspases-3, -8 and -9 were detected, and the anti-apoptotic molecule, Bax, also increased. Activation of STAT1/3, NF-kappa B (p65 and p50 subunits), pAKT and pERK decreased, and p-PTEN increased. There was also a significant reduction of hTERT at 12 h and upregulation of gamma-H(2)A(X) and CHK1/2 molecules at 24 h. Thus, KML001 appears to have antitumor activity against MM by inhibiting various oncogenic signaling pathways. It may be useful for treating MM.en_US
dc.description.sponsorshipThis study was conducted in the Hanyang University Hospital Clinical Laboratory, and this study was supported by Komipharm International Co., Ltd., Gyeonggi-do, Korea.en_US
dc.language.isoen_USen_US
dc.publisherSPANDIDOS PUBL LTDen_US
dc.subjectmultiple myelomaen_US
dc.subjectKML001en_US
dc.subjectcell cycleen_US
dc.subjectcell signalingen_US
dc.subjecttelomereen_US
dc.titleAntitumoral effect of arsenic compound, sodium metaarsenite (KML001), on multiple myeloma cellsen_US
dc.typeArticleen_US
dc.relation.no6-
dc.relation.volume51-
dc.identifier.doi10.3892/ijo.2017.4161-
dc.relation.page1739-1746-
dc.relation.journalINTERNATIONAL JOURNAL OF ONCOLOGY-
dc.contributor.googleauthorKim, Seo Ju-
dc.contributor.googleauthorKim, Eun Shil-
dc.contributor.googleauthorKim, Sujong-
dc.contributor.googleauthorUhm, Jieun-
dc.contributor.googleauthorWon, Young Woong-
dc.contributor.googleauthorPark, Byeong Bae-
dc.contributor.googleauthorChoi, Jung Hye-
dc.contributor.googleauthorLee, Young Yiul-
dc.relation.code2017001068-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidleeyy-
Appears in Collections:
COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE